{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:38Z","timestamp":1791335618506,"version":"4.3.1"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metastasis is a complex, multistep process that begins with the epithelial\u2013mesenchymal transition (EMT). Circulating tumor cells (CTC) are believed to have undergone EMT and thus lack or express low levels of epithelial markers commonly used for enrichment and\/or detection of such cells. However, most current CTC detection methods target only EpCAM and\/or cytokeratin (CK) to enrich epithelial CTCs, resulting in failure to recognize other, perhaps more important, CTC phenotypes that lack expression of these markers. Here, we describe a population of complex aneuploid CTCs that do not express CK or CD45 antigen in patients with breast, ovarian, or colorectal cancer. These cells were not observed in healthy subjects. We show that the primary epithelial tumors were characterized by similar complex aneuploidy, indicating conversion to an EMT phenotype in the captured cells. Collectively, our study provides a new method for highly efficient capture of previously unrecognized populations of CTCs.<\/jats:p>\n                  <jats:p>Significance: Current assays for CTC capture likely miss populations of cells that have undergone EMT. Capture and study of CTCs that have undergone EMT would allow a better understanding of the mechanisms driving metastasis. Cancer Discovery; 1(7); 580\u201386. \u00a92011 AACR.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 539<\/jats:p>","DOI":"10.1158\/2159-8290.cd-11-0215","type":"journal-article","created":{"date-parts":[[2011,11,3]],"date-time":"2011-11-03T23:33:47Z","timestamp":1320363227000},"page":"580-586","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":196,"title":["A Novel Platform for Detection of CK+ and CK\u2212 CTCs"],"prefix":"10.1158","volume":"1","author":[{"given":"Chad V.","family":"Pecot","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farideh Z.","family":"Bischoff","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Ann","family":"Mayer","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina L.","family":"Wong","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam","family":"Pham","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Bottsford-Miller","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Stone","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne G.","family":"Lin","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmavathi","family":"Jaladurgam","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Won","family":"Roh","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"},{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake W.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Merritt","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony J.","family":"Pircher","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Mikolajczyk","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpa M.","family":"Nick","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Celestino","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Eng","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Ellis","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"},{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Deavers","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"},{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"},{"name":"Authors' Affiliations:\u20081Division of Cancer Medicine, Departments of 2Gynecologic Oncology, 3Gastrointestinal Medical Oncology, 4Pathology, 5Surgical Oncology, 6Cancer Biology, 7Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas; 8Biocept Inc., San Diego, California; and 9Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2011,12,13]]},"reference":[{"key":"2022060622200780800_bib1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrc822","article-title":"Epithelial-mesenchymal transitions in tumour progression","volume":"2","author":"Thiery","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2022060622200780800_bib2","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nature06385","article-title":"Isolation of rare circulating tumour cells in cancer patients by microchip technology","volume":"450","author":"Nagrath","year":"2007","journal-title":"Nature"},{"key":"2022060622200780800_bib3","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2022060622200780800_bib4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/annonc\/mdq030","article-title":"All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer","volume":"21","author":"Coumans","year":"2010","journal-title":"Ann Oncol"},{"key":"2022060622200780800_bib5","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1158\/1055-9965.EPI-08-1173","article-title":"Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors","volume":"18","author":"Goodman","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060622200780800_bib6","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N Engl J Med"},{"key":"2022060622200780800_bib7","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1158\/1078-0432.CCR-05-2821","article-title":"Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival","volume":"12","author":"Hayes","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022060622200780800_bib8","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1158\/0008-5472.CAN-08-3667","article-title":"Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res"},{"key":"2022060622200780800_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1056\/NEJMoa0800668","article-title":"Detection of mutations in EGFR in circulating lung-cancer cells","volume":"359","author":"Maheswaran","year":"2008","journal-title":"N Engl J Med"},{"key":"2022060622200780800_bib10","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/jcb.21148","article-title":"The role of the organ microenvironment in the biology and therapy of cancer metastasis","volume":"101","author":"Fidler","year":"2007","journal-title":"J Cell Biochem"},{"key":"2022060622200780800_bib11","first-page":"3584","article-title":"Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts","volume":"44","author":"Tarin","year":"1984","journal-title":"Cancer Res"},{"key":"2022060622200780800_bib12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrclinonc.2010.171","article-title":"Molecular mechanisms of metastasis in breast cancer\u2014clinical applications","volume":"7","author":"Mego","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2022060622200780800_bib13","first-page":"2883","article-title":"Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues","volume":"47","author":"Momburg","year":"1987","journal-title":"Cancer Res"},{"key":"2022060622200780800_bib14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/472273a","article-title":"Cancer theory faces doubts","volume":"472","author":"Ledford","year":"2011","journal-title":"Nature"},{"key":"2022060622200780800_bib15","doi-asserted-by":"crossref","first-page":"034119","DOI":"10.1063\/1.3623748","article-title":"Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device","volume":"5","author":"Dickson","year":"2011","journal-title":"Biomicrofluidics"},{"key":"2022060622200780800_bib16","first-page":"49","article-title":"Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors","volume":"27","author":"Rao","year":"2005","journal-title":"Int J Oncol"},{"key":"2022060622200780800_bib17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10549-010-1163-x","article-title":"HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial","volume":"124","author":"Fehm","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"2022060622200780800_bib18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1309\/N6X5MB24BP42KP20","article-title":"Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays","volume":"126","author":"Mayr","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"2022060622200780800_bib19","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/gcc.20699","article-title":"Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer","volume":"48","author":"Camps","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"2022060622200780800_bib20","first-page":"2073","article-title":"Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant","volume":"8","author":"Fehm","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2022060622200780800_bib21","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jama.2010.292","article-title":"Circulating tumor cells revisited","volume":"303","author":"Cristofanilli","year":"2010","journal-title":"JAMA"},{"key":"2022060622200780800_bib22","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/bcr2333","article-title":"Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients","volume":"11","author":"Aktas","year":"2009","journal-title":"Breast Cancer Res"},{"key":"2022060622200780800_bib23","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1158\/1541-7786.MCR-10-0490","article-title":"Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers","volume":"9","author":"Armstrong","year":"2011","journal-title":"Mol Cancer Res"},{"key":"2022060622200780800_bib24","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2353\/ajpath.2009.090078","article-title":"Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy","volume":"175","author":"Hou","year":"2009","journal-title":"Am J Pathol"},{"key":"2022060622200780800_bib25","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1186\/bcr2896","article-title":"Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients","volume":"13","author":"Kallergi","year":"2011","journal-title":"Breast Cancer Res"},{"key":"2022060622200780800_bib26","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00418-008-0435-6","article-title":"The human keratins: biology and pathology","volume":"129","author":"Moll","year":"2008","journal-title":"Histochem Cell Biol"},{"key":"2022060622200780800_bib27","doi-asserted-by":"crossref","first-page":"R69","DOI":"10.1186\/bcr2131","article-title":"Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients","volume":"10","author":"Deng","year":"2008","journal-title":"Breast Cancer Res"},{"key":"2022060622200780800_bib28","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022060622200780800_bib29","doi-asserted-by":"crossref","first-page":"18392","DOI":"10.1073\/pnas.1012539107","article-title":"Isolation of circulating tumor cells using a microvortex-gene\u00adrating herringbone-chip","volume":"107","author":"Stott","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060622200780800_bib30","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1158\/1078-0432.CCR-03-0114","article-title":"Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer","volume":"10","author":"Woelfle","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2022060622200780800_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/jcp.48.1.26","article-title":"Cytokeratin intermediate filament expression in benign and malignant breast disease","volume":"48","author":"Heatley","year":"1995","journal-title":"J Clin Pathol"},{"key":"2022060622200780800_bib32","doi-asserted-by":"crossref","first-page":"861341","DOI":"10.1155\/2010\/861341","article-title":"Cytomorphology of circulating colorectal tumor cells: a small case series","volume":"2010","author":"Marrinucci","year":"2010","journal-title":"J Oncol"},{"key":"2022060622200780800_bib33","doi-asserted-by":"crossref","DOI":"10.1007\/s10147-010-0173-3","article-title":"Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer","author":"Hayashi","year":"2011  15","journal-title":"Int J Clin Oncol"},{"key":"2022060622200780800_bib34","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1158\/0008-5472.CAN-11-1254","article-title":"Circulating tumor cell isolation and diagnostics: toward routine clinical use","volume":"71","author":"van de Stolpe","year":"2011","journal-title":"Cancer Res"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/1\/7\/580\/1812776\/580.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/1\/7\/580\/1812776\/580.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T18:20:32Z","timestamp":1654539632000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/1\/7\/580\/2501\/A-Novel-Platform-for-Detection-of-CK-and-CK"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,1]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,12,13]]},"published-print":{"date-parts":[[2011,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-11-0215","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.22528979","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22528979.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6545828.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6545828","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,1]]}}}